Ambenonium chloride

Ambenonium chloride

File:Ambenonium.svg
Systematic (IUPAC) name
2,2'-[(1,2-Dioxoethane-1,2-diyl)diimino]bis[N-(2-chlorobenzyl)-N,N-diethylethanaminium]
Clinical data
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a699058
Routes of administration	Oral
Pharmacokinetic data
Bioavailability	Low
Identifiers
CAS Number	7648-98-8 Y
ATC code	N07AA30 (WHO)
PubChem	CID: 8288
DrugBank	DB01122 N
ChemSpider	7987 Y
UNII	L16PUN799N Y
KEGG	D01001 Y
ChEBI	CHEBI:2628 Y
ChEMBL	CHEMBL1652 N
Chemical data
Formula	C28H42Cl2N4O2+2
Molecular mass	537.564 g/mol
SMILES [Cl-].[Cl-].Clc1ccccc1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](Cc2ccccc2Cl)(CC)CC
InChI InChI=1S/C28H40Cl2N4O2.2ClH/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30;;/h9-16H,5-8,17-22H2,1-4H3;2*1H Y Key:DXUUXWKFVDVHIK-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Ambenonium (as ambenonium dichloride, trade name Mytelase) is a cholinesterase inhibitor used in the management of myasthenia gravis.

It is classified as reversible.

Mechanism of action

Ambenonium exerts its actions against myasthenia gravis by competitive reversible inhibition of acetylcholinesterase, the enzyme responsible for the hydrolysis of acetylcholine. Myasthenia gravis occurs when the body produces antibodies against acetylcholine receptors, and thus inhibits signal transmission across the myoneural junction. Ambenonium reversibly binds acetylcholinesterase, inactivates it and therefore increases levels of acetylcholine. This, in turn, facilitates transmission of impulses across the myoneural junction and effectively treats the disease.

Indications

Ambenonium is used to treat muscle weakness due to disease or defect of the neuromuscular junction (myasthenia gravis).

Ambenonium was withdrawn from the market in the United States in 2010.